US OptionsDetailed Quotes

ETNB241220P7500

Watchlist

0.35
0.000.00%

15min DelayClose Nov 29 13:00 ET

0.00High0.00Low

89bio Stock Discussion

Jaguar8

Oct 15 07:51

NEWS

$89bio (ETNB.US)$
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
89bio (Nasdaq: ETNB) announced that new analyses from the Phase 2b ENLIVEN trial of pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis will be presented at the 75th Annual AASLD The Liver Meeting® 2024. The presentations include four poster sessions focusing on:
Bio...

Meltyy

May 16 01:19

🔔 RA Capital Q1 ‘24* Holdings Released... 🐳

» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...

Jaguar8

May 14 07:01

$89bio (ETNB.US)$
NEWS
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
89bio has initiated the Phase 3 ENLIGHTEN-Cirrhosis trial for pegozafermin in patients with MASH and compensated cirrhosis (F4). This is the first FGF21 analog to reach this trial stage for this patient subset. The trial will involve 760 patients, assessing fibrosis regression at 24 months, potentially supporting ac...